Skip to main content
SpringerLink
Log in

Modulation of Malignant Melanoma Growth with Vitamins and Other Chemically-Defined Biological Modifiers

  • Chapter
Clinical Management of Malignant Melanoma

Part of the book series: Cancer Treatment and Research ((CTAR,volume 21))

Abstract

Malignant melanoma is a fascinating disease which has been extensively studied for a number of different biological properties in murine models. Despite this wealth of data, successful treatment of human malignant melanoma has been confined to surgery with other therapies impacting little on the survival of the 40–50% of patients who relapse following adequate excision. This is particularly important in that the incidence of melanoma has been rising rapidly in the last decade, with the disease now the second fastest increasing malignancy in terms of incidence in the United States [1]. Although a large number of new and effective cytotoxic anticancer agents has entered the clinic in the past twenty years, none (alone or in combination) have significantly altered either the recurrence rate from malignant melanoma after surgery or survival after metastatic disease [2, 3]. A number of investigators have turned to alternative strategies, including immunomo-dulation [4], manipulation of the melanin synthesis pathway [5], or the use of high dose or hyperfractionated radiotherapy [6].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Third National Cancer Survey: Incidence data (SEER), Dhew Publication No. 78-1837.

    Google Scholar 

  2. Salmon SE, Jones SE: Adjuvant therapy of cancer III. New York: Grune and Stratton, 1981, pp 271–254.

    Google Scholar 

  3. Luce JK: Chemotherapy of melanoma. Sem Oncology 2: 179–185, 1975.

    CAS  Google Scholar 

  4. Marton DL, Eilber FR, Holmes EC, Sparks FC, Ramming KP: Present status of BCG immunotherapy of malignant melanoma. Cancer Immun Immunother 1: 93–98, 1976.

    Google Scholar 

  5. Graham DG, Tiffany SM, Vogel FS: The toxicity of melanin precursors. J Invest Derm 70: 113–116, 1978.

    Article  PubMed  CAS  Google Scholar 

  6. Brayer TJ, Oleson JR, Meyskens FL Jr: High-dose vs. low-dose radiotherapy for brain metastases from malignant melanoma, (submitted).

    Google Scholar 

  7. Pawson BA, Ehmann CW, Itri LM, Sherman MI: Retinoids at the threshold: Their biological significance and therapeutic potential. J Med Chem 25: 1269–1277, 1982.

    Article  PubMed  CAS  Google Scholar 

  8. Meyskens FL Jr: Modulation of abnormal growth by retinoids: A clinical perspective of the biological phenomenon. Life Sciences 28: 2323–2327, 1981.

    Article  PubMed  CAS  Google Scholar 

  9. Sporn MB: Retinoids and carcinogenesis. Nut Rev 35: 65–69, 1977.

    Article  CAS  Google Scholar 

  10. Lowe NJ, Connor MJ, Breeding J: Inhibition of ultraviolet-B induced epidermal ornithine decarboxylase and carcinogenesis by topical retinoic. In: Proceedings of the First International Congress on the Modulation and Mediation of Cancer by Vitamins, Meyskens FL Jr, Prasad KN (eds). New York: Karger, pp. 78–80, 1983.

    Google Scholar 

  11. Lichti U, Patterson E, Hennings H, Yuspa SH: Differential retinoic acid inhibition of ornithine decarboxylase induction by 12-0-tetradecanoylphorbol-13-acetate and by germicidinal ultraviolet light. Cancer Res. 41: 49–54, 1981.

    PubMed  CAS  Google Scholar 

  12. Kripke ML: Speculations on the role of ultraviolet radiation in the development of malignant melanoma. J Natl Cancer Inst 63: 541–548, 1979.

    PubMed  CAS  Google Scholar 

  13. Lotan R: Effects of vitamin A and its analogues on normal and neoplastic cells. Biochem Biophys Acta 605: 33–91, 1980.

    PubMed  CAS  Google Scholar 

  14. Strickland S, Mahalavi V: The induction of differentiation in teratocarcinoma cells by retinoic acid. Cell 15: 393–403, 1978.

    Article  PubMed  CAS  Google Scholar 

  15. Lotan R: Retinoic acid stimulates and phorbol–myristate acetate inhibits melanogenesis in cultures of murine S91 melanoma cells. J Cell Biol 79: CD144, 1978.

    Google Scholar 

  16. Nicolson GL, Lotan R, Rios A: Heterogeneous in vitrosensitivities of metastatic B16 melanoma sublines and clones to retinoic acid or BCNU. Cancer Treat Rep 65 supplement: 71–74, 1981.

    PubMed  CAS  Google Scholar 

  17. Meyskens FL Jr, Fuller BB: Characterization of the effects of different retinoids on the growth and differentiation of a human melanoma cell line and selected subclones. Cancer Res 40: 2194–2196, 1980.

    PubMed  CAS  Google Scholar 

  18. Meyskens FL Jr, Salmon SE: Inhibition of human melanoma colony formation by retinoids. Cancer Res 39: 4055–4057, 1979.

    PubMed  Google Scholar 

  19. Lotan R: Different susceptability of human melanoma and breast carcinoma cell lines to retinoic acid-induced growth inhibition. Cancer Res 39: 1014–1019, 1979.

    PubMed  CAS  Google Scholar 

  20. Levine N, Meyskens FL Jr: Topical vitamin A acid therapy for cutaneous metastatic melanoma. The Lancet ii: 224–226, 1980.

    Google Scholar 

  21. Meyskens FL Jr, Gilmartin E, Alberts DS, Levine NS, Brooks R, Salmon SE, Surwit EA: Activity of isotretinoin against squamous cell cancers and preneoplastic lesions. Cancer Treat Rep 66: 1315–1319, 1982.

    PubMed  Google Scholar 

  22. Meyskens FL Jr, Aapro MS, Voakes JB, Moon TE, Gilmartin E: A stratified, randomized adjuvant study of BCG ± vitamin A in stage I and II malignant melanoma. In: Adjuvant therapy of cancer III, Samon SE, Jones SE (eds). New York: Grune and Stratton, 1981, pp 217–224.

    Google Scholar 

  23. Dennert G, Lotan R: Effects of retinoic acid on the immune system: Stimulation of T killer cell induction. Eur J Immunol 8: 23–29, 1978.

    Article  PubMed  CAS  Google Scholar 

  24. Sidell N, Famatiga E, Golub SH: Augmentation of human thymocyte proliferative responses by retinoic acid. Exp Cell Biol 49: 239–245, 1981.

    PubMed  CAS  Google Scholar 

  25. Felix EL, Loyd B, Cohn MH: Inhibition of the growth and development of a transplantable murine melanoma by vitamin A. Science 189: 886–888, 1975.

    Article  PubMed  CAS  Google Scholar 

  26. Oikawa A, Nakayasu M: Stimulation of melanogenesis in cultured melanoma cells by calciferols. FEBS Letters 42: 32–35, 1974.

    Article  PubMed  CAS  Google Scholar 

  27. Colton K, Colston MJ, Feldman D: 1,25-dihydroxy vitamin D3 and malignant melanoma: The presence of receptors and inhibition of cell growth in culture. Endo 108: 1083–1086, 1981.

    Google Scholar 

  28. Prasad KN, Edwards-Prasad J: Effects of tocopherol (vitamin E) acid succinate on morphological alterations and growth inhibition in melanoma cells in culture. Cancer Res 42: 550–555, 1982.

    PubMed  CAS  Google Scholar 

  29. Prasad KN, Edwards-Prasad J: Effects of tocopherol (vitamin E) acid succinate on morphological alterations and growth inhibition in melanoma cells in culture. Cancer Res 42: 550–555, 1982.

    PubMed  CAS  Google Scholar 

  30. Meyskens FL Jr: The endocrinology of malignant melanoma. Rev Endocrone-Related Cancer 9: 5–13, 1981.

    Google Scholar 

  31. Horn D, Buzard RL: Growth inhibition by glucocorticoids in RPM1 3460 melanoma cells. Cancer Res 41: 3155–3160, 1981.

    PubMed  CAS  Google Scholar 

  32. Buzard RL, Hutchins TW, Hawkins EF, Markland JS Jr, Horn D: Clonal variants of a melanoma cell line sensitive to growth inhibition by dexamethasone. Exp Cell Res 138:385– 396, 1982.

    Article  Google Scholar 

  33. Hawkins EF, Mutchens TW, Fligiel S, Horn D, Markland FS Jr: Glucocorticoids and melanoma receptor properties of dexamethasone sensitive and resistant tumors. J Steroid Biochem 16: 673–681, 1982.

    Article  PubMed  CAS  Google Scholar 

  34. Hutchens TW, Hawkins EF, Markland FS Jr: Identification of transformed glucocorticoid receptor from dexamethasone resistant melanoma. J Steroid Biochem 16: 705–711, 1982.

    Article  PubMed  CAS  Google Scholar 

  35. Adachi K, Kondo S, Hu F: Suppression of growth of mouse melanoma by cortisone. Nature 220: 1132–1133, 1968.

    Article  PubMed  CAS  Google Scholar 

  36. Bahkoo HS, Paolini NS, Milholland RJ, Lopez RE, Rosen F: Glucocorticoid receptors and the effect of glucocorticoids on the growth of B–16 melanoma. Cancer Res 41: 1695–1701, 1981.

    Google Scholar 

  37. Fidler IJ, Lieber S: Quantitative analysis of the mechanism of glucocorticoid enhancement of experimental metastasis. Res Communun Chem Pathol Pharmacol 4: 607–613, 1972.

    CAS  Google Scholar 

  38. Zeidman I: The fate of circulating tumor cells: A mechanism of cortisone action in increasing metastasis. Cancer Res 22: 501–503, 1962.

    PubMed  CAS  Google Scholar 

  39. Abromowitz J, Chavin W: Glucocorticoid modulation of adrenocorticotropin-induced melanogenesis in the Cloudman S–91 melanoma in vitro. Exp Cell Biol 46: 268–276, 1978.

    Google Scholar 

  40. Neifeld JP, Lippman ME, Fisher RJ: Receptors for steroid hormones in human melanoma. Surg Forum 27: 108–110, 1976.

    PubMed  CAS  Google Scholar 

  41. Bhakoo HS, Milholland RJ, Lopez R, Karakonsis C, Rosen F: High incidence and characterization of glucocorticoid receptors in human malignant melanoma. JNCI 66: 21–25, 1981.

    PubMed  CAS  Google Scholar 

  42. Bojar H, Stuhldreier B, Becher R, Koldovsky U, Goerz G, Merk H, Staib W: Gradient centrifugation analysis of steroid hormone binding in human malignant melanoma. Anticancer Res 2: 245–250, 1982.

    PubMed  CAS  Google Scholar 

  43. Bregman MD, Peters E, Sander D, Meyskens FL Jr: Dexamethasone, prostaglandin A, and retinoic acid modulation of murine and human melanoma cells grown in soft agar. JNCI 71: 927–932, 1983.

    PubMed  CAS  Google Scholar 

  44. Stringfellow DA, Fitspatrick FA: Prostaglandin D2 controls pulmonary metastasis of malignant melanoma cells. Nature 282: 76–78, 1979.

    Article  PubMed  CAS  Google Scholar 

  45. Fitspatrick FA, Stringfellow DA: Prostaglandin D2 formation by malignant melanoma cells correlates inversely with cellular metastatic potential. Proc Nat Acad Sci 76: 1765–1769, 1979.

    Article  Google Scholar 

  46. Bregman MD, Meyskens FL Jr: In vitromodulation of human and murine melanoma growth by prostanoid analogues. Prostaglandin, 26: 449–456, 1983.

    Article  CAS  Google Scholar 

  47. Honn KV, Cicone B, Skoff A: Prostacyclin: A potent antimetastatic agent. Science 212: 1270–1272, 1981.

    Article  PubMed  CAS  Google Scholar 

  48. Honn KV, Cicone B, Skoff A: Prostacyclin: A potent antimetastatic agent. Science 212: 1270–1272, 1981.

    Article  PubMed  CAS  Google Scholar 

  49. Honn KV, Meyer J: Thromboxanes and prostacyclin: Positive and negative modulators of tumor growth. Biophys Res Commun 102: 1122–1129, 1981.

    Article  CAS  Google Scholar 

  50. Goodwin JS: Prostaglandin synthetase inhibitors as immunoadjuvants in the treatment of cancer. J Immunopharm 2: 397–424, 1980.

    Article  CAS  Google Scholar 

  51. Goodwin JS, Webb DR: Regulation of the immune response by prostaglandins. Clin Immunol Immunopathol 15: 106–111, 1980.

    Article  PubMed  CAS  Google Scholar 

  52. Honn KV, Dunn II Jr, Morgan LR, Bienkowski M, Marnett LJ: Inhibition of DNA synthesisin Harding-Passey melanoma cells by prostaglandins At and A2. comparison with chemotherapeutic agents. Biochem Biophys Res Commun 87: 795–801, 1979.

    Article  PubMed  CAS  Google Scholar 

  53. Honn KV, Romine M, Skoff A: Prostaglandin analogs as inhibitors of tumor cell DNA synthesis. Proc Soc Exp Biol and Med 166: 562–567, 1981.

    CAS  Google Scholar 

  54. Turner WA, Bennet DR, Thompson KC, Taylor JD, Honn KV: Structural activity requirement for PGA effects on tumor cell growth and differentiation. In: Prostaglandins and Cancer, Powler TJ, Bockman RS, Honn KV, Ramwell P (eds), Vol. 2, Prostaglandin and related lipids. New York: Alan Liss, Inc., pp 265–368, 1982.

    Google Scholar 

  55. Santoro MG, Philpott GW, Jaffe BM: Inhibition of tumor growth in vivoand in vitroby prostaglandin E. Nature 263: 777–779, 1976.

    Article  CAS  Google Scholar 

  56. Santoro MG, Philpott GW, Jaffe BM: Dose–dependent inhibition of B–16 melanoma growth in vivoby a synthetic analogues of PGE2. Prostaglandins 14: 645–651, 1977.

    Article  PubMed  CAS  Google Scholar 

  57. Favalli C, Gavari E, Santoro MG, Santucci L, Jaffe BM: The effect of PGA on the immune response in B-16 melanoma–bearing mice. Prostaglandins 19: 587–593, 1980.

    Article  PubMed  CAS  Google Scholar 

  58. Bregman MD, Sander D, Meyskens FL Jr: Prostaglandin A1 and E1 inhibit the plating efficiency and proliferation of murine melanoma cells (Cloudman S-91) in soft agar. Biochem Biophys Res Commun 104: 1080–1086, 1982.

    Article  PubMed  CAS  Google Scholar 

  59. Bregman MD, Meyskens FL Jr: Inhibition of human malignant melanoma colony forming cells in vitroby prostaglandin A1. Cancer Res 43: 1642–1645, 1983.

    PubMed  CAS  Google Scholar 

  60. Culp BR, Titus BG, Lands WEM: Inhibition of prostaglandin biosynthesis by eichosapentaenoic acid. Prostaglandins and Medicine 3: 269–278, 1979.

    Article  PubMed  CAS  Google Scholar 

  61. Mamont PS, Duchesne MC, Grove J, Bey P: Antiproliferative properties of D, L-a-difluoromethylornithine in cultured cells: A consequence of the irreversible inhibition of ornithine decarboxylase. Biochem Biophys Res Commun 81: 58–66, 1978.

    Article  PubMed  CAS  Google Scholar 

  62. Hung DT, Deen DF, Seidenfeld J, Marton J: Sensitization of 9L rat brain gliosarcoma cells to l,3-bis(2-choroethyl)-l-nitrosourea by a-difluoromethylornithine, an ornithine decarboxylase inhibitor. Cancer Res 41: 2783–2785, 1981.

    PubMed  CAS  Google Scholar 

  63. Marton LJ, Levin VA, Hervatin SJ, Koch–Weser J, McCann P, Sjoerdsma A: Potentiation of the antitumor therapeutic effects of l,3-bis(2-choroethyl)-l-nitrosourea by a-difluoromethylornithine, an ornithine decarboxylase inhibitor. Cancer Res 41: 4426–4431, 1981.

    PubMed  CAS  Google Scholar 

  64. Bartholeyns J, Koch-Weser J: Effects of a-difluoromethylornithne alone and combined with adriamycin or vindisine on LI210 leukemia in mice, EMTG solid tumors in mice, and solid tumors induced by injection of hepatoma tissue culture cells in rats. Cancer Res 41: 5158–5161, 1981.

    PubMed  CAS  Google Scholar 

  65. Chapman SK: Antitumor effects of vitamin A and inhibitors of ornithine decarboxylase in cultured neuroblastoma and glioma cells. Life Sci 26: 1359–1366, 1980.

    Article  PubMed  CAS  Google Scholar 

  66. Seidenfeld J, Deen DF, Marton LJ: Depletion of intracellular polyamic content does not alter the survival of 9L rat brain tumor cells after x–irradiation. Int J Rad Biol 38: 223–229, 1980.

    Article  CAS  Google Scholar 

  67. Oredsson SM, Deen DF, Marton LJ: Decreased cytotoxicity of cis-diammine dichloro platinum II by a-difluoromethylornithine depletion of polyamines in 9L rat brain tumor cells in vitro. Cancer Res 42: 1296–1299, 1982.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Marvin D. Bregman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Frank L. Meyskens Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Hematology/Oncology Cancer Center, University of Texas Medical Branch, Galveston, Texas, USA

    John J. Costanzi

Rights and permissions

Reprints and permissions

Copyright information

© 1984 Martinus Nijhoff Publishers, Boston

About this chapter

Cite this chapter

Bregman, M.D., Meyskens, F.L. (1984). Modulation of Malignant Melanoma Growth with Vitamins and Other Chemically-Defined Biological Modifiers. In: Costanzi, J.J. (eds) Clinical Management of Malignant Melanoma. Cancer Treatment and Research, vol 21. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-3813-0_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-3813-0_5

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-3815-4

  • Online ISBN: 978-1-4613-3813-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation